Current treatment of nontuberculous mycobacteriosis: an update

Bibliography

• Wayne LG, Kubica GP. Genus Mycobacterium lehman and neumann 1896. In: Sneath PHA, Mair NS, Sharpe ME, Holt JG, editors. Bergey's Manual of Systematic Bacteriology. 1st edition. Williams & Wilkins; Baltimore: 1986. p. 1436-57
   Google Scholar
• Euzeby JP. List of Prokaryotic names with standing in nomenclature - genus Mycobacterium. 30 december 2011; Available from: http://www.bacterio.cict.fr/m/mycobacterium.html
   Google Scholar
• Falkinham JO III. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107(2):356-67
   PubMed Web of Science ®Google Scholar
• Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17(3):419-24
   PubMed Web of Science ®Google Scholar
• CLSI. Susceptibility testing of Mycobacteria, nocardiae, and other aerobic actinomycetes; aprproved standard. In: CLSI, editor. 2nd edition. CLSI; Wayne, PA: 2011
   Google Scholar
• Arend SM, van Soolingen D, Ottenhoff TH. Diagnosis and treatment of lung infection with nontuberculous mycobacteria. Curr Opin Pulm Med 2009;15(3):201-8
   PubMed Web of Science ®Google Scholar
• Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010;23(2):185-90
   PubMed Web of Science ®Google Scholar
• McGrath EE, Blades Z, McCabe J, Nontuberculous mycobacteria and the lung: from suspicion to treatment. Lung 2010;188(4):269-82
   PubMed Web of Science ®Google Scholar
• McGrath EE, McCabe J, Anderson PB, Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Prac 2008;62(12):1947-55
   PubMed Web of Science ®Google Scholar
• Esteban J, Ortiz-Perez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother 2009;10(17):2787-99
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, Kosters K, Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009;59(Pt 9):2277-82
   PubMed Web of Science ®Google Scholar
• Ben Salah I, Cayrou C, Raoult D, Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., novel species in the Mycobacterium avium complex. Int J Syst Evol Microbiol 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Williams MM, Yakrus MA, Arduino MJ, Structural analysis of biofilm formation by rapidly and slowly growing nontuberculous mycobacteria. Appl Environ Microbiol 2009;75(7):2091-8
   PubMed Web of Science ®Google Scholar
• Behr MA, Falkinham JO III. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol 2009;4(8):1009-20
   PubMed Web of Science ®Google Scholar
• Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect 2009;15(10):906-10
   PubMed Web of Science ®Google Scholar
• Yew WW, Sotgiu G, Migliori GB. Update in tuberculosis and nontuberculous mycobacterial disease 2010. Am J Respir Crit Care Med 2011;184(2):180-5
   PubMed Web of Science ®Google Scholar
• Kim RD, Greenberg DE, Ehrmantraut ME, Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178(10):1066-74
   PubMed Web of Science ®Google Scholar
• Amir J. Non-tuberculous mycobacterial lymphadenitis in children: diagnosis and management. Isr Med Assoc J 2010;12(1):49-52
   PubMed Web of Science ®Google Scholar
• Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 2009;15(9):1351-8; quiz 544
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Chang E, Yamashita S, Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15(10):1556-61
   PubMed Web of Science ®Google Scholar
• Simons S, van Ingen J, Hsueh PR, Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011;17(3):343-9
   PubMed Web of Science ®Google Scholar
• Elston D. Nontuberculous mycobacterial skin infections: recognition and management. Am J Clin Dermatol 2009;10(5):281-5
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367-416
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Laan T, Dekhuijzen R, In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010;35(2):169-73
   PubMed Web of Science ®Google Scholar
• Deshpande D, Srivastava S, Meek C, Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 2010;54(6):2534-9
   PubMed Web of Science ®Google Scholar
• Sim YS, Park HY, Jeon K, Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med J 2010;51(6):888-94
   PubMed Web of Science ®Google Scholar
• Jenkins PA, Campbell IA, Banks J. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial diseases and an assessment of the value of immunotherapy by The British Thoracic Society. Thorax 2008;63:627-34
   PubMed Web of Science ®Google Scholar
• Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124(4):1482-6
   PubMed Web of Science ®Google Scholar
• Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999;21(2):137-52
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KH, Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE1-4
   Google Scholar
• Deshpande D, Srivastava S, Meek C, Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010;54(5):1728-33
   PubMed Web of Science ®Google Scholar
• Martin-Casabona N, Bahrmand AR, Bennedsen J, Nontuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberculosis Lung Dis 2004;8(10):1186-93
   PubMed Web of Science ®Google Scholar
• Bittner MJ, Horowitz EA, Safranek TJ, Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996;22(6):1109-10
   PubMed Web of Science ®Google Scholar
• Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9(2):177-215
   PubMed Web of Science ®Google Scholar
• Bloch KC, Zwerling L, Pletcher MJ, Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998;129(9):698-704
   PubMed Web of Science ®Google Scholar
• Santin M, Alcaide F, Benitez MA, Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiol Infect 2004;132(3):425-32
   PubMed Web of Science ®Google Scholar
• Alcaide F, Richter I, Bernasconi C, Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol 1997;35(8):1959-64
   PubMed Web of Science ®Google Scholar
• Picardeau M, Prod'Hom G, Raskine L, Genotypic characterization of five subspecies of Mycobacterium kansasii. J Clin Microbiol 1997;35(1):25-32
   PubMed Web of Science ®Google Scholar
• Richter E, Niemann S, Rusch-Gerdes S, Identification of Mycobacterium kansasii by using a DNA probe (AccuProbe) and molecular techniques. J Clin Microbiol 1999;37(4):964-70
   PubMed Web of Science ®Google Scholar
• Taillard C, Greub G, Weber R, Clinical implications of Mycobacterium kansasii species heterogeneity: swiss National Survey. J Clin Microbiol 2003;41(3):1240-4
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mann LB, Wilson RW, Molecular analysis of Mycobacterium kansasii isolates from the United States. J Clin Microbiol 2004;42(1):119-25
   PubMed Web of Science ®Google Scholar
• Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007;20(2):198-203
   PubMed Web of Science ®Google Scholar
• Santin M, Alcaide F. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int J Tuberculosis Lung Dis 2003;7(7):673-7
   PubMed Web of Science ®Google Scholar
• Witzig RS, Fazal BA, Mera RM, Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995;21(1):77-85
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 1999;43(3):537-42
   PubMed Web of Science ®Google Scholar
• Ahn CH, Lowell JR, Ahn SS, Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983;128(6):1048-50
   PubMed Web of Science ®Google Scholar
• Research_Committee_British_Thoracic_Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994;49(5):442-5
   PubMed Web of Science ®Google Scholar
• Sauret J, Hernandez-Flix S, Castro E, Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995;76(2):104-8
   PubMedGoogle Scholar
• Kaustova J, Chmelik M, Ettlova D, Disease due to Mycobacterium kansasii in the Czech Republic: 1984 – 89. Tuber Lung Dis 1995;76(3):205-9
   PubMedGoogle Scholar
• Santin M, Dorca J, Alcaide F, Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 2009;33(1):148-52
   PubMed Web of Science ®Google Scholar
• Alcaide F, Calatayud L, Santin M, Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004;48(12):4562-5
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Dunbar D, Brown BA, Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994;18(5):736-43
   PubMed Web of Science ®Google Scholar
• Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother 2001;45(11):3056-8
   PubMed Web of Science ®Google Scholar
• Fassbender M, Lode H, Schiller C, Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1996;1(4):235-43
   PubMedGoogle Scholar
• Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc) 2000;36(4):229-44
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kipps J, Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46(5):1475-80
   PubMed Web of Science ®Google Scholar
• Cynamon MH, Elliott SA, DeStefano MS, Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 2003;52(2):306-7
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Crist CJ, Mann LB, In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003;47(5):1736-8
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003;37(9):1178-82
   PubMed Web of Science ®Google Scholar
• Tompkins JC, Witzig RS. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberculosis Lung Dis 2007;11(3):331-7
   PubMed Web of Science ®Google Scholar
• Johnson PD, Azuolas J, Lavender CJ, Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007;13(11):1653-60
   PubMed Web of Science ®Google Scholar
• Portaels F, Meyers WM, Ablordey A, First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008;2(3):e178
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Phillips R, Asiedu K, Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010;54(9):3678-85
   PubMed Web of Science ®Google Scholar
• Nakanaga K, Hoshino Y, Yotsu RR, Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. J Clin Microbiol 2011;49(11):3829-36
   PubMed Web of Science ®Google Scholar
• Debacker M, Aguiar J, Steunou C, Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005;11(4):584-9
   PubMed Web of Science ®Google Scholar
• Beissner M, Awua-Boateng NY, Thompson W, A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana. Am J Trop Med Hyg 2010;83(5):1059-65
   PubMed Web of Science ®Google Scholar
• Organization WH. Buruli ulcer meetings in Cotonou, Benin. 2009. Available from: http://www.who.int/buruli/archives/en/index.html [Cited 13 December 2011]
   Google Scholar
• Nienhuis WA, Stienstra Y, Thompson WA, Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010;375(9715):664-72
   PubMed Web of Science ®Google Scholar
• Gordon CL, Buntine JA, Hayman JA, All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis 2010;4(11):e770
   PubMed Web of Science ®Google Scholar
• O'Brien DP, McDonald A, Callan P, Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012;6(1):e1473
   PubMed Web of Science ®Google Scholar
• Nijland HM, Ruslami R, Suroto AJ, Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45(8):1001-7
   PubMed Web of Science ®Google Scholar
• Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria. Curr opin Pulm Med 2010;16(3):251-6
   PubMed Web of Science ®Google Scholar
• Andrejak C, Lescure FX, Pukenyte E, Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009;64(4):291-6
   PubMed Web of Science ®Google Scholar
• Danesh-Clough T, Theis JC, van der Linden A. Mycobacterium xenopi infection of the spine: a case report and literature review. Spine (Phila Pa 1976 2000;25(5):626-8
   PubMed Web of Science ®Google Scholar
• Salliot C, Desplaces N, Boisrenoult P, Arthritis due to Mycobacterium xenopi: a retrospective study of 7 cases in France. Clin Infect Dis 2006;43(8):987-93
   PubMed Web of Science ®Google Scholar
• Sanchez R, Font B, Pi J. Mycobacterium xenopi flexor tenosynovitis. J Hand Surg Eur Vol 2010;35(6):516-17
   PubMed Web of Science ®Google Scholar
• Satyanarayana G, Heysell SK, Scully KW, Mycobacterial infections in a large Virginia hospital, 2001 – 2009. BMC Infect Dis 2011;11:113
   PubMed Web of Science ®Google Scholar
• Phyffer GE. Mycobacterium: general characteristics, laboratory detection, and staining procedures. In: Murray PR, Baron EJ, Jorgensen JM, Landry ML, Phaller MA, editors. Manual of Clinical Microbiology. 9th edition. ASM Press; Washington, D.C: 2010. p. 543-72
   Google Scholar
• Duarte JN, Marques N, Barroso L, Cervical abscess in an immunocompetent patient with Mycobacterium malmoense pulmonary disease. Oral Maxillofac Surg 2011; [Epub ahead of print] doi: 10.1007/s10006-011-0306-5
   Google Scholar
• Hoefsloot W, van Ingen J, de Lange WC, Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009;34(4):926-31
   PubMed Web of Science ®Google Scholar
• Abgueguen P, Rabier V, Mahaza C, Mycobacterium malmoense: an underestimated nontuberculous mycobacterium. Diagn Microbiol Infect Dis 2010;66(1):98-100
   PubMed Web of Science ®Google Scholar
• Claesson G, Bennet R, Eriksson M, Nerve dysfunction following surgical treatment of cervical non-tuberculous mycobacterial lymphadenitis in children. Acta Paediatr 2011;100(2):299-302
   PubMed Web of Science ®Google Scholar
• Tortoli E, Mattei R, Russo C, Mycobacterium lentiflavum, an emerging pathogen? J Infect 2006;52(6):e185-7
   PubMedGoogle Scholar
• van Ingen J, Totten SE, Heifets LB, Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012;39(2):173-6
   PubMed Web of Science ®Google Scholar
• Philip J, Bhatia S, Sugar A, Mycobacterium lentiflavum–a cause of infections in the head and neck: case report and literature review. J Oral Maxillofac Surg 2011;69(4):1114-16
   PubMed Web of Science ®Google Scholar
• Niobe SN, Bebear CM, Clerc M, Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol 2001;39(5):2030-2
   PubMed Web of Science ®Google Scholar
• Marshall HM, Carter R, Torbey MJ, Mycobacterium lentiflavum in drinking water supplies, Australia. Emerg Infect Dis 2011;17(3):395-402
   PubMed Web of Science ®Google Scholar
• Conger NG, O'Connell RJ, Laurel VL, Mycobacterium simae outbreak associated with a hospital water supply. Infect Control Hosp Epidemiol 2004;25(12):1050-5
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, Dekhuijzen PN, Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008;31(1):106-9
   PubMed Web of Science ®Google Scholar
• Narang R, Narang P, Jain AP, Disseminated disease caused by Mycobacterium simiae in AIDS patients: a report of three cases. Clin Microbiol Infect 2010;16(7):912-14
   PubMed Web of Science ®Google Scholar
• Charles P, Lortholary O, Dechartres A, Mycobacterium genavense infections: a retrospective multicenter study in France, 1996 – 2007. Medicine (Baltimore) 2011;90(4):223-30
   PubMed Web of Science ®Google Scholar
• Thomsen VO, Dragsted UB, Bauer J, Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 1999;37(12):3901-5
   PubMed Web of Science ®Google Scholar
• Rammaert B, Couderc LJ, Rivaud E, Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. BMC Infect Dis 2011;11:311
   PubMed Web of Science ®Google Scholar
• Doggett JS, Strasfeld L. Disseminated Mycobacterium genavense with pulmonary nodules in a kidney transplant recipient: case report and review of the literature. Transpl Infect Dis 2011;13(1):38-43
   PubMed Web of Science ®Google Scholar
• Bogdan C, Kern P, Richter E, Systemic infection with Mycobacterium genavense following immunosuppressive therapy in a patient who was seronegative for human immunodeficiency virus. Clin Infect Dis 1997;24(6):1245-7
   PubMed Web of Science ®Google Scholar
• Sompolinsky D, Lagziel A, Rosenberg I. Further studies of a new pathogenic mycobacterium (M. haemophilum sp. nov.). Can J Microbiol 1979;25(2):217-26
   PubMed Web of Science ®Google Scholar
• Dawson DJ, Jennis F. Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum. J Clin Microbiol 1980;11(2):190-2
   PubMed Web of Science ®Google Scholar
• Saubolle MA, Kiehn TE, White MH, Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 1996;9(4):435-47
   PubMed Web of Science ®Google Scholar
• Shah MK, Sebti A, Kiehn TE, Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001;33(3):330-7
   PubMed Web of Science ®Google Scholar
• Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis 2005;41(11):1569-75
   PubMed Web of Science ®Google Scholar
• Cohen YH, Amir J, Ashkenazi S, Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis 2008;14(9):1437-9
   PubMed Web of Science ®Google Scholar
• Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011;24(4):701-17
   PubMed Web of Science ®Google Scholar
• Minani TJ, Saubolle MA, Yu E, Mycobacterium haemophilum as a novel etiology of cervical lymphadenitis in an otherwise healthy adult patient. J Clin Microbiol 2010;48(7):2636-9
   PubMed Web of Science ®Google Scholar
• Bicmen C, Coskun M, Gunduz AT, Nontuberculous mycobacteria isolated from pulmonary specimens between 2004 and 2009: causative agent or not? New Microbiol 2010;33(4):399-403
   PubMed Web of Science ®Google Scholar
• Maloney JM, Gregg CR, Stephens DS, Infections caused by Mycobacterium szulgai in humans. Rev Infect Dis 1987;9(6):1120-6
   PubMedGoogle Scholar
• Marks J, Jenkins PA, Tsukamura M. Mycobacterium szulgai–a new pathogen. Tubercle 1972;53(3):210-14
   PubMedGoogle Scholar
• Krusche-Mandl I, Decramer A, Boltuch-Sherif J, Non-tuberculous mycobacterial infections of the hand and wrist: a retrospective review of five cases from a single centre. Handchir Mikrochir Plast Chir 2009;41(5):283-7
   PubMed Web of Science ®Google Scholar
• Ohta H, Miyauchi E, Ebina M, A case of cutaneous infection caused by mycobacterium szulgai with progression to acute respiratory distress syndrome. Clin Med Insights Case Rep 2011;4:29-33
   PubMedGoogle Scholar
• Meyer JJ, Gelman SS. Multifocal osteomyelitis due to Mycobacterium szulgai in a patient with chronic lymphocytic leukemia. J Infect 2008;56(2):151-4
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, de Lange WC, Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008;46(8):1200-5
   PubMed Web of Science ®Google Scholar
• Sanchez-Alarcos JM, De Miguel-Diez J, Bonilla I, Pulmonary infection due to Mycobacterium szulgai. Respiration 2003;70(5):533-6
   PubMed Web of Science ®Google Scholar
• Kim HY, Kim BJ, Kook Y, Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010;54(6):347-53
   PubMed Web of Science ®Google Scholar
• Leao SC, Tortoli E, Euzeby JP, Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011;61(Pt 9):2311-13
   PubMed Web of Science ®Google Scholar
• De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006;42(12):1756-63
   PubMed Web of Science ®Google Scholar
• Set R, Shastri J. Laboratory aspects of clinically significant rapidly growing mycobacteria. Indian J Med Microbiol 2011;29(4):343-52
   PubMed Web of Science ®Google Scholar
• Brown-Elliot BA, Wallace RJ Jr. Rapidly Growing Mycobacteria. In: Schlossberg D, editor. Tuberculosis and Nontuberculous Mycobacterial Infections. 6th edition. ASM Press; Washington, D.C: 2011. p. 565-77
   Google Scholar
• Regnier S, Cambau E, Meningaud JP, Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009;49(9):1358-64
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Kuijper EJ. Rapidly growing mycobacteria: emerging pathogens in cosmetic procedures of the skin. Clin Infect Dis 2009;49(9):1365-8
   PubMed Web of Science ®Google Scholar
• Bechara C, Macheras E, Heym B, Mycobacterium abscessus skin infection after tattooing: first case report and review of the literature. Dermatology 2010;221(1):1-4
   PubMed Web of Science ®Google Scholar
• Rodriguez-Blanco I, Fernandez LC, Suarez-Penaranda JM, Mycobacterium chelonae infection associated with tattoos. Acta Derm Venereol 2011;91(1):61-2
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr, Tichindelean C, A five year community/hospital outbreak of Mycobacterium porcinum related to public water supplies. J Clin Microbiol 2011;49(12):4231-8
   PubMed Web of Science ®Google Scholar
• Esteban J, Martin-de-Hijas NZ, Fernandez AI, Epidemiology of infections due to non-pigmented rapidly growing Mycobacteria diagnosed in an urban area. Eur J Clin Microbiol 2008;27(10):951-7
   Google Scholar
• Nessar R, Cambau E, Reyrat JM, Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67(4):810-8
   PubMed Web of Science ®Google Scholar
• Esteban J, Martin-de-Hijas NZ, Garcia-Almeida D, Prevalence of erm methylase genes in clinical isolates of nonpigmented, rapidly growing mycobacteria. Clin Microbiol Infect 2009;15(10):919-23
   PubMed Web of Science ®Google Scholar
• Esteban J, Martin-de-Hijas NZ, Ortiz-Perez A, Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria. Int J Antimicrob Agents 2009;34(5):454-6
   PubMed Web of Science ®Google Scholar
• Nash KA, Andini N, Zhang Y, Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006;50(10):3476-8
   PubMed Web of Science ®Google Scholar
• Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53(4):1367-76
   PubMed Web of Science ®Google Scholar
• Nessar R, Reyrat JM, Murray A, Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011;66(8):1719-24
   PubMed Web of Science ®Google Scholar
• Esteban J, Gadea I, Torres MV, A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex. J Chemother 2002;14(6):547-53
   PubMed Web of Science ®Google Scholar
• Fernandez-Roblas R, Esteban J, Cabria F, In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000;44(1):181-2
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Ward SC, Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45(3):764-7
   PubMed Web of Science ®Google Scholar
• Fernandez-Roblas R, Martin-de-Hijas NZ, Fernandez-Martinez AI, In vitro activity of tigecycline and 10 other antimicrobials against non-pigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008;52(11):4184-6
   PubMed Web of Science ®Google Scholar
• Wallace RJJ, Brown-Elliott BA, Crist CJ, Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46(10):3164-7
   PubMed Web of Science ®Google Scholar
• Bastian S, Brossier F, Wichlacz C, Daptomycin is not active against rapidly growing mycobacteria. J Med Microbiol 2010;59(Pt 1):135-6
   PubMed Web of Science ®Google Scholar
• Griffith DE. The talking Mycobacterium abscessus blues. Clin Infect Dis 2011;52(5):572-4
   PubMed Web of Science ®Google Scholar
• Uyan ZS, Ersu R, Oktem S, Mycobacterium abscessus infection in a cystic fibrosis patient: a difficult to treat infection. Int J Tuberculosis Lung Dis 2010;14(2):250-1
   PubMed Web of Science ®Google Scholar
• van Ingen J, de Zwaan R, Dekhuijzen RP, Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009;59(5):324-31
   PubMed Web of Science ®Google Scholar
• Jarand J, Levin A, Zhang L, Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52(5):565-71
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Wilson RW, Clinical and laboratory features of Mycobacterium porcinum. J Clin Microbiol 2004;42(12):5689-97
   PubMed Web of Science ®Google Scholar
• Patil R, Patil T, Schenfeld L, Mycobacterium porcinum peritonitis in a patient on continuous ambulatory peritoneal dialysis. J Gen Intern Med 2011;26(3):346-8
   PubMed Web of Science ®Google Scholar
• Sakuramoto Y, Goto K, Okamoto K, Mycobacterium marinum infection causing extensive cutaneous ulcerations and deep abscesses on the extremities: a case report. Nippon Naika Gakkai Zasshi 2010;99(4):831-3
   PubMedGoogle Scholar
• El Amrani MH, Adoui M, Patey O, Upper extremity Mycobacterium marinum infection. Orthop Traumatol Surg Res 2010;96(6):706-11
   PubMed Web of Science ®Google Scholar
• Savini H, Morel F, Vedy S, Sporotrichoid topographic distribution and Mycobacterium marinum grown on a subdermal contraceptive implant. Rev Med Interne 2011;32(4):e49-51
   PubMedGoogle Scholar
• Salik D, Del Marmol V. Refractory hand ulceration: a case of chronic ulceration and sporotrichoid spread in a fish tank hobbyist following Mycobacterium marinum infection. Case Rep Dermatol 2011;3(2):137-41
   PubMedGoogle Scholar
• Giordano CN, Kalb RE, Brass C, Nodular lymphangitis: report of a case with presentation of a diagnostic paradigm. Dermatol Online J 2010;16(9):1
   PubMedGoogle Scholar
• Zeegelaar JE, Faber WR. Imported tropical infectious ulcers in travelers. Am J Clin Dermatol 2008;9(4):219-32
   PubMed Web of Science ®Google Scholar
• Streit M, Bohlen LM, Hunziker T, Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 2006;16(1):79-83
   PubMed Web of Science ®Google Scholar
• Tran H, Kamino H, Walters RF. Mycobacterium marinum infection. Dermatol Online J 2008;14(10):7
   PubMedGoogle Scholar
• Aubry A, Jarlier V, Escolano S, Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother 2000;44(11):3133-6
   PubMed Web of Science ®Google Scholar
• Nenoff P, Klapper BM, Mayser P, Infections due to Mycobacterium marinum: a review. Hautarzt 2011;62(4):266-71
   PubMed Web of Science ®Google Scholar
• Osorio F, Magina S, Carvalho T, Mycobacterium marinum skin infection with tenosynovitis successfully treated with doxycycline. Dermatol Online J 2010;16(9):7
   PubMedGoogle Scholar
• Dolenc-Voljc M, Zolnir-Dovc M. Delayed diagnosis of Mycobacterium marinum infection: a case report and review of the literature. Acta Dermatovenerol Alp Panonica Adriat 2010;19(2):35-9
   PubMedGoogle Scholar
• Brown BA, Wallace RJJ, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992;36(9):1987-90
   PubMed Web of Science ®Google Scholar
• Parrish N, Luethke R, Dionne K, Case of Mycobacterium marinum infection with unusual patterns of susceptibility to commonly used antibiotics. J Clin Microbiol 2011;49(5):2056-8
   PubMed Web of Science ®Google Scholar
• Cummins DL, Delacerda D, Tausk FA. Mycobacterium marinum with different responses to second-generation tetracyclines. Int J Dermatol 2005;44(6):518-20
   PubMed Web of Science ®Google Scholar
• Zambrano MM, Kolter R. Mycobacterial biofilms: a greasy way to hold it together. Cell 2005;123(5):762-4
   PubMed Web of Science ®Google Scholar
• Pang JM, Layre E, Sweet L, The polyketide Pks1 contributes to biofilm formation in Mycobacterium tuberculosis. J Bacteriol 2012;194(3):715-21
   PubMed Web of Science ®Google Scholar
• Fux CA, Stoodley P, Hall-Stoodley L, Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003;1(4):667-83
   PubMedGoogle Scholar
• Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001;9(2):50-2
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93
   PubMed Web of Science ®Google Scholar
• Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004;2(2):95-108
   PubMed Web of Science ®Google Scholar
• Esteban J, Martin-de-Hijas NZ, Kinnari TJ, Biofilm development by potentially pathogenic non-pigmented rapidly growing mycobacteria. BMC Microbiol 2008;8:184
   PubMed Web of Science ®Google Scholar
• Martin-de-Hijas NZ, Garcia-Almeida D, Ayala G, Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria. Clin Microbiol Infect 2009;15(10):931-6
   PubMed Web of Science ®Google Scholar
• Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to planktonic bacteria. Antimicrob Agents Chemother 2008;52(6):2019-26
   PubMed Web of Science ®Google Scholar
• Ortiz-Perez A, Martin-de-Hijas N, Alonso-Rodriguez N, Importance of antibiotic penetration in the antimicrobial resistance of biofilm formed by non-pigmented rapidly growing mycobacteria against amikacin, ciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin 2011;29(2):79-84
   PubMed Web of Science ®Google Scholar